Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy
Gilda Cennamo(Federico II University Hospital), Giovanni Cennamo(Federico II University Hospital), Daniela Montorio(University of Naples Federico II), Raffaele Liuzzi(Institute of Biostructure and Bioimaging), Maria Angelica Breve(Regione Campania), Mario Giuliano(Regione Campania), A. Farella(Regione Campania), Sabino De Placido, Elide Matano(Regione Campania), Luca D’ Andrea(University of Naples Federico II)
Cited by 22
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273